Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Kissei Pharma (4547 JP): FY27 Guidance Revealed, Tavneos Hiccup Amid Linzagolix Positives

Kissei Pharmaceutical (4547 JP): Beova & Tavneos Still Key, Linzagolix Japan Approval Next Trigger

Kissei Pharmaceutical (4547 JP): Steady FY25, Licensing Fees To Drag FY26, Margins To Stay Strong

Kissei Pharmaceutical (4547 JP): Guidance Upward Revision a Positive; Beova & Tavneos Still Key

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kissei-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:18303:1" rel="noopener">Kissei Pharmaceutical (4547 JP)</a> reported 11% YoY jump in revenue during 9MFY26 driven by Beova, Tavneos and IT services amidst price revision pressures and generic competition.</li>
<li>Management reiterated FY26 guidance numbers. The company expects FY26 revenue to rise 8% YoY to ¥95.5B. Extraordinary income would help company post a net profit of ¥12.7B in FY26.</li>
<li>The next big trigger would be Linzagolix launch in Japan for treatment of uterine fibroids and its further geographic and indication expansion.  </li>
</ul>



Kissei Pharmaceutical (4547 JP) reported 11% YoY jump in revenue during 9MFY26 driven by Beova, Tavneos and IT services amidst price revision pressures and generic competition.
Management reiterated FY26 guidance numbers. The company expects FY26 revenue to rise 8% YoY to ¥95.5B. Extraordinary income would help company post a net profit of ¥12.7B in FY26.
The next big trigger would be Linzagolix launch in Japan for treatment of uterine fibroids and its further geographic and indication expansion.  


Kissei Pharma (4547 JP): 9MFY26 Stable, Guidance Reiterated, Linzagolix Japan Launch Awaited